SynthesisObesity surgery2025
Transoral Outlet Reduction for Dumping Syndrome After Roux-En-Y Gastric Bypass: a Comprehensive Systematic Review and Meta-Analysis.
Synthesis in Obesity surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Post-Bariatric Surgery Complications and the Role of Endoscopic Intervention.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDumping syndrome is a complication of Roux-en-Y gastric bypass (RYGB) surgery that can significantly affect quality of life. Transoral outlet reduction (TORe) is a minimally invasive endoscopic procedure that reduces the size of the gastrojejunal anastomosis (GJA) through ablation and/or endoscopic suturing, primarily used to address weight regain after RYGB. Emerging evidence highlights the feasibility and safety of TORe as a treatment for medically refractory dumping syndrome. This meta-analysis aims to evaluate the efficacy and safety of TORe for dumping syndrome.
methodsA systematic search of PubMed, Embase, and Web of Science was conducted through December 2024. Primary outcomes included clinical success (defined as sustained symptom improvement without requiring repeat TORe or revisional surgery at last follow-up) and the mean difference in pre- and post-procedural Sigstad's score assessments. Secondary outcomes included rates of post-TORe surgery, repeat TORe, and serious adverse events. Pooled rate estimates and mean differences (MD) with the corresponding 95% confidence intervals (CI) were calculated using random-effects models.
resultsSix studies with 333 post-RYGB patients with dumping syndrome were included. The pooled clinical success of TORe was 83% (95% CI 71%-90%, I
conclusionsOur findings suggest that TORe is a safe and effective minimally invasive treatment for patients with medically refractory dumping syndrome. Further prospective studies with longer follow-up durations are warranted to validate these findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.